{"id":983972,"date":"2026-07-23T01:05:08","date_gmt":"2026-07-23T05:05:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-reports-half-year-2026-financial-results-and-provides-second-quarter-business-update\/"},"modified":"2026-07-23T01:05:08","modified_gmt":"2026-07-23T05:05:08","slug":"argenx-reports-half-year-2026-financial-results-and-provides-second-quarter-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/argenx-reports-half-year-2026-financial-results-and-provides-second-quarter-business-update\/","title":{"rendered":"argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update"},"content":{"rendered":"
\n

\n

\n Strong second quarter performance with $1.5 billion in global product net sales, representing 60% year-over-year growth and 17% quarter-over-quarter growth <\/i>\n <\/p>\n

\n Successfully launched VYVGART and VYVGART Hytrulo in anti-AChR antibody negative (\u201cseronegative\u201d) gMG, expanding patient reach to all gMG serotypes<\/i>\n <\/p>\n

\n Registrational autoimmune myositis study readout on track for 3Q26, marking a key milestone for VYVGART expansion into rheumatology<\/i>\n <\/p>\n

\n Registrational MMN study readout for empasiprubart on track for 4Q26, supporting a second pipeline-in-a-product opportunity <\/i>\n <\/p>\n

\n Management to host conference call today at 2:30 PM CET (8:30 AM ET)<\/i>\n <\/p>\n

\n July 23, 2026 7:00 AM CET<\/b>\n <\/p>\n

\n Amsterdam, the Netherlands<\/b> – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced its half year 2026 results and provided a second quarter business update.<\/p>\n

\u201cOur strong second quarter performance reflects continued execution of our Vision 2030 strategy and our commitment to accelerate immunology innovation,\u201d said Karen Massey, Chief Executive Officer. \u201cDuring the quarter, we further strengthened our leadership in FcRn with the launch of the expanded label for VYVGART and VYVGART Hytrulo to now include all gMG serotypes, providing physicians with a single treatment option for the broadest adult gMG patient population. With important registrational study readouts in the second half, as well as continued progress with our early-stage pipeline, we are advancing the next wave of innovation, reinforcing our ambition to build a leading multi-asset immunology company.\u201d<\/p>\n

\n Vision 2030<\/b>
\n
argenx continues to advance its \u2018Vision 2030\u2019 anchored in the ambition to treat 50,000 patients globally with its medicines, secure 10 labeled indications, and progress five pipeline candidates into registrational development by 2030.<\/p>\n

\n Expanding global VYVGART opportunity and shaping the long-term future of FcRn<\/b>
\n
VYVGART\u00ae (IV: efgartigimod alfa-fcab; SC: efgartigimod alfa and hyaluronidase-qvfc) is the first-and-only approved treatment for all serotypes of adult patients living with generalized myasthenia gravis (gMG). It is also approved for chronic inflammatory demyelinating polyneuropathy (CIDP) globally, and primary immune thrombocytopenia (ITP) in Japan. As the leading targeted biologic in MG and CIDP, argenx is progressing multiple label expansions while building the future of FcRn by advancing novel FcRn pipeline candidates and new delivery modalities.<\/p>\n